Trials / Approved For Marketing
Approved For MarketingNCT04320693
Expanded Access for IMMU-132
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMMU-132 | IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles |
Timeline
- First posted
- 2020-03-25
- Last updated
- 2021-08-19
Source: ClinicalTrials.gov record NCT04320693. Inclusion in this directory is not an endorsement.